Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study

J Clin Exp Hematop. 2023 Sep 28;63(3):197-200. doi: 10.3960/jslrt.23015. Epub 2023 Jul 28.

Authors

Masuho Saburi¹, Kazuki Okuhiro², Natsumi Yoshida², Takami Haruyama², Yui Moroga², Yuka Yanai², Kazuhito Itani², Kuniko Takano², Shuhei Honda³, Keiji Ono⁴, Manami Iwanaga⁵, Hitohiro Sasaki⁵, Miyuki Abe⁵, Kazuhiro Kohno⁵, Toshiyuki Nakayama⁵, Eiichi Ohtsuka¹, Masao Ogata²

Affiliations

¹ Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
² Department of Hematology, Oita University Hospital, Oita, Japan.
³ Department of Hematology, JCHO Nankai Medical Center, Oita, Japan.
⁴ Department of Hematology, Almeida Memorial Hospital, Oita, Japan.
⁵ Department of Hematology, Oita Kouseiren Tsurumi Hospital, Oita, Japan.

No abstract available

Keywords: anti-CD20 antibody; bendamustine; cytomegalovirus; follicular lymphoma; infection.

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Bendamustine Hydrochloride / adverse effects
Humans
Lymphoma, Follicular* / drug therapy
Rituximab / adverse effects

Substances

Bendamustine Hydrochloride
Rituximab
Antibodies, Monoclonal